Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  eflornithine
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 34 for your search:
Start Over
Phase III Randomized Study of Eflornithine in Patients with Low Grade, Superficial Transitional Cell Carcinoma of the Bladder. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: ILEX-DFMO341, N01-CN-25434-01, UCLA-9812049, UF-453-1998, WCCC-CO-98803, NCI-G99-1509, NCT00003814
Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
Phase: Phase III
Type: Prevention
Status: Completed
Age: 40 to 80
Sponsor: NCI
Protocol IDs: NCI-2009-00880, UCI 97-05, R01CA088078, UCIRVINE-UCI-2002-2261, NCT00118365
Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer
Phase: Phase III
Type: Prevention
Status: Completed
Age: 21 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067928, U01CA077158, WCCC-CO-9737, NCI-P00-0155, NCT00005884
Phase I/II Chemoprevention Study of Eflornithine (DFMO) in Patients At Risk for Colorectal Carcinoma (Summary Last Modified 02/98)
Phase: Phase II, Phase I
Type: Prevention
Status: Closed
Age: Over 18
Sponsor: NCI
Protocol IDs: WCCC-CO-9221, NCI-P97-0096
Phase I/II Chemotherapy with DFMO/MGBG in Patients with Adenocarcinoma of the Prostate
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-8525A, NCI-T85-0043D, T85-0043
Phase II Chemoprevention Study of Difluoromethylornithine (DFMO) in Patients With Superficial Bladder Cancer
Phase: Phase II
Type: Prevention, Screening
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: WCCC-CO-9285, NCI-G97-1213
Phase II Study of DiFluoroMethylOrnithine (DFMO) in Breast Dysplasia with Biomarker Abnormalities (Summary Last Modified 05/1999)
Phase: Phase II
Type: Prevention
Status: Closed
Age: 30-55 with exceptions
Sponsor: NCI
Protocol IDs: KUMC-HSC-6916-96, NCI-P97-0080
Phase II Randomized, Double Blind, Placebo-Controlled Study of Eflornithine (DFMO) in Women with Breast Neoplasia (Summary Last Modified 03/98)
Phase: Phase II
Type: Prevention
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UAB-9509, NCI-P97-0082
Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: CDR0000065763, P30CA046592, CCUM-9555, NCI-P97-0094, NCT00003076
Phase II Randomized Study of Eflornithine versus Placebo for the Treatment of Leukoplakic Dysplasia (Summary Last Modified 12/1999)
Phase: Phase II
Type: Prevention
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: FCCC-94021, NCI-P97-0095
Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: ID92-026, P30CA016672, MDA-ID-92026, NCI-P00-0149, CDR0000067921, NCT00006079
Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer
Phase: Phase II
Type: Prevention
Status: Closed
Age: 35 to 70
Sponsor: NCI, Other
Protocol IDs: CDR0000068110, UCIRVINE-97-18, UCIRVINE-U01-CA-81886-01, NCI-P00-0164, NCT00006101
Phase II Pilot Immunotherapy with Interferon and Chemotherapy with DFMO in Patients with Kaposi's Sarcoma and the Acquired Immune Deficiency Syndrome
Phase: Phase II
Type: Treatment
Status: Completed
Age: no age specified
Sponsor: NCI
Protocol IDs: NCI-84-C-179, NCI-T84-0477N, T84-0477
Phase II Sequential Chemotherapy with DFMO Followed by MeGAG for Refractory Lymphoma or CLL
Phase: Phase II
Type: Treatment
Status: Completed
Age: no age specified
Sponsor: NCI
Protocol IDs: RPMI-PPC-764, NCI-T83-0886D
Phase II Study of DFMO in Patients with Recurrent Malignant Gliomas (Summary Last Modified 07/91)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: MDA-DM-88130, NCI-T88-0236H, T88-0236
Phase II Study of Recombinant Interferon Alpha-2a/Eflornithine in Patients with Recurrent Gliomas (Summary Last Modified 11/90)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-867202, NCI-T89-0006C, T89-0006
Phase II Pilot Study of DFMO Following Transurethral Resection of Superficial and Superficially Invasive Transitional Cell Carcinoma of the Urinary Bladder
Phase: Phase II
Type: Prevention
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-895151, EST-C-0490, MAYO-895151, I89-0001, NCI-P91-0008
Phase IIb Cancer Prevention Trial of the Effect of the Polyamine Synthesis Inhibitor DFMO on Colon Mucosa (Summary Last Modified 09/95)
Phase: Phase II
Type: Prevention
Status: Closed
Age: 40 to 80
Sponsor: Other
Protocol IDs: UCI-DFMO/COLON, NCI-P92-0007
Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000353198, UAB-9921, UAB-F990728039, NCT00086736
Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients
Phase: Phase II
Type: Prevention
Status: Completed
Age: 21 and over
Sponsor: Other
Protocol IDs: 2001-414, CO00318, NCT00204789
Eflornithine Plus Sulindac in Preventing Colorectal Cancer in Patients With Benign Colorectal Polyps
Phase: Phase II
Type: Prevention
Status: Completed
Age: 40 to 80
Sponsor: NCI, Other
Protocol IDs: CDR0000067922, 1997-96, NCI-P00-0150, UCIRVINE-97-05, NCT00005882
Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis
Phase: Phase II
Type: Prevention, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000068767, P01CA027502, UARIZ-HSC-0072, NCI-H01-0075, NCT00021294
Start Over